Strides Pharma Science has entered into a definitive agreement to sell a majority stake in its technology services subsidiary, Pivot Path, to a consortium led by private equity firm Ascent Capital. The transaction values the business at ₹230 crore on a post-money basis, allowing the Bengaluru-based drugmaker to realize approximately ₹1 billion while retaining a 20% equity stake in the entity.
Why is Strides Pharma divesting its stake?
The divestment serves as a strategic move to unlock value from a specialized business unit while ensuring the parent company maintains exposure to its future growth. According to the company, the transaction is designed to support the next phase of Pivot Path’s development. Strides Pharma will transition Pivot Path from a wholly owned subsidiary to an associate company once the deal closes. The valuation was determined by an independent assessment conducted by a merchant banker registered with the Securities and Exchange Board of India (Sebi).
What is the role of Pivot Path in the pharmaceutical sector?
Pivot Path provides a suite of consulting, regulatory compliance, digital transformation, and technology-enabled services tailored for pharmaceutical and life sciences firms. The company was originally incubated within Arco Lab, the global capability centre of Strides. It became an independent entity following a Scheme of Arrangement approved by the National Company Law Tribunal (NCLT) in May 2026.
For the financial year 2026, the business recorded revenue of ₹144.7 crore and an Ebitda of ₹16.9 crore. These figures include revenue derived from services provided directly to its parent company, Strides Pharma.
How will the new capital be used?
As part of the agreement, Pivot Path is set to receive a ₹50 crore primary capital infusion. This funding is earmarked for expansion and investments in new technology platforms, specifically those driven by artificial intelligence. Ascent Capital has indicated that it intends to leverage this capital to help Pivot Path increase its footprint in the global life sciences industry by integrating domain expertise with AI-driven solutions.
Key Financial Details
- Transaction Valuation: ₹230 crore (post-money)
- Strides Cash Realization: Approximately ₹1 billion
- Retained Stake: Approximately 20%
- Primary Capital Infusion: ₹50 crore
- FY26 Revenue: ₹144.7 crore
- FY26 Ebitda: ₹16.9 crore
The shift in ownership marks a transition for Pivot Path as it moves toward scaling its operations as an associate entity, supported by the external backing of the Ascent Capital-led consortium.
Worth a look